Long-term dopamine replacement therapy with l-DOPA in Parkinson's disease often leads to the development of abnormal involuntary movements known as l-DOPA-induced dyskinesia. Growing evidence suggests that, following dopamine cell loss, serotonin neurons acting as surrogates for dopaminergic processes take up l-DOPA, convert it to dopamine and release it in an unregulated fashion that precipitates dyskinesia. Although most studies have focused on serotonin 5-HT 1 receptor stimulation as an antidyskinetic strategy, targeting the serotonin transporter modulation of dopamine activity has been overlooked. Therefore, in the current study, selective serotonin reuptake inhibitors were tested for their ability to reduce l-DOPA-and apomorphine-induced dyskinesia. In Experiments 1 and 2, hemi-parkinsonian rats were primed with l-DOPA until stable dyskinesia developed. Rats in Experiment 1 were administered the selective serotonin reuptake inhibitors paroxetine, citalopram or fluoxetine, followed by l-DOPA. Abnormal involuntary movements and forepaw adjusting steps were recorded to determine the effects of these compounds on dyskinesia and motor performance, respectively. Brains were collected on the final test day, after which striatal and raphe monoamines were examined via high-performance liquid chromatography. In Experiment 2, dyskinesias were measured after selective serotonin reuptake inhibitors and apomorphine. Serotonin reuptake inhibitors dose-dependently attenuated l-DOPA-but not apomorphine-induced dyskinesia, and preserved l-DOPA efficacy. Neurochemically, serotonin transporter inhibition enhanced striatal and raphe serotonin levels and reduced its turnover, indicating a potential mechanism of action. The present results support targeting serotonin transporters to improve Parkinson's disease treatment and provide further evidence for the role of the serotonin system in l-DOPA's effects.
Introduction
Since its discovery in the 1960s, dopamine (DA) replacement therapy with l-DOPA has remained the gold-standard symptomatic treatment for Parkinson's disease (PD) (Birkmayer & Hornykiewicz, 1961; Smith et al., 2012) . Unfortunately, its chronic administration leads to debilitating abnormal involuntary movements (AIMs) termed l-DOPA-induced dyskinesia (LID) that occur in nearly 90% of patients with PD within a decade (Ahlskog & Muenter, 2001) . The preponderance of LID in late PD has led to a concerted effort to identify potential adjuncts with favorable antidyskinetic profiles that also maintain l-DOPA's antiparkinsonian efficacy.
Several pre-synaptic and post-synaptic mechanisms likely contribute to LID development and expression, including abnormal motor learning in corticostriatal afferents, fluctuations in striatal DA and enhanced striatal DA receptor signaling (de la Fuente-Fernández et al., 2004; Lindgren et al., 2010; Feyder et al., 2011; Huang et al., 2011) . Interestingly, compelling evidence has implicated raphestriatal serotonin (5-HT) neurons as a major source of striatal DA in the parkinsonian brain, as they contain the requisite transport and enzymatic machinery to take up, convert and release l-DOPA-derived DA (Arai et al., 1995; Maeda et al., 2005) . Unfortunately, these neurons also lack DA transporters and D 2 autoreceptors and are thus incapable of regulating the exaggerated DA efflux that portends LID (Carta et al., 2007; Eskow et al., 2009; Navailles et al., 2010) .
As such, current 5-HT antidyskinetic strategies have focused on stimulation of 5-HT 1A and ⁄ or 5-HT 1B receptors to moderate release of l-DOPA-derived DA (Muñoz et al., 2008; Zhang et al., 2008; Bishop et al., 2009; Eskow et al., 2009) . However, accumulating evidence points to a potential role for the 5-HT transporter (SERT) in DA transmission (Yamato et al., 2001; Kannari et al., 2006; Navailles et al., 2010; Larsen et al., 2011) , implicating a mechanism by which LID might be modulated. Indeed, Rylander et al. (2010) recently reported that SERT is upregulated in the striata of dyskinetic rats, monkeys, and humans, whereas others have demonstrated that removal of SERT-expressing terminals from raphestriatal projections reduces LID (Carta et al., 2007; Eskow et al., 2009 ). Despite preliminary support for the hypothesis that selective 5-HT reuptake inhibitors (SSRIs) may alter LID (Durif et al., 1995; Chung et al., 2005; Dekundy et al., 2007; Kuan et al., 2008) , this has not been systematically addressed.
Therefore, in the current series of studies, we examined the effects of the well-known and oft-employed antidepressant SSRIs, paroxetine, citalopram, and fluoxetine, against l-DOPA-induced AIMs, their potential modulation of l-DOPA's antiparkinsonian efficacy and their effects on DA agonist-induced dyskinesia with apomorphine. Finally, tissue levels of striatal and raphe monoamines were measured by highperformance liquid chromatography (HPLC) to examine neurochemical correlates to behavior.
Materials and methods

Animals
Adult male Sprague-Dawley rats were used (225-250 g upon arrival; Taconic Farms, NY, USA). Animals were housed in plastic cages (22 cm high, 45 cm deep and 23 cm wide) and had free access to standard laboratory chow (Rodent Diet 5001; Lab Diet, Brentwood, MO, USA) and water. The colony room was maintained on a 12 ⁄ 12 h light ⁄ dark cycle (lights on at 07:00 h) at a temperature of 22-23°C. Animals were maintained and protocols were approved in accordance with the guidelines of the Institutional Animal Care and Use Committee of Binghamton University and the 'Guide for the Care and Use of Laboratory Animals' (Institute of Laboratory Animal Resources, National Academic Press; NIH publication number 85-23, revised 1996).
6-Hydroxydopamine lesion surgeries
At 1 week after arrival, all rats (N = 38) received unilateral 6-hydroxydopamine (6-OHDA) (Sigma, St Louis, MO, USA) lesions of the left medial forebrain bundle to destroy DA neurons . Desipramine HCl (25 mg ⁄ kg, i.p.; Sigma) was given 30 min prior to 6-OHDA injection to prevent the loss of norepinephrine (NE) neurons. Rats were anesthetized with inhalant isoflurane (2-3%; Sigma) in oxygen (2.5 L ⁄ min), and placed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). The coordinates for 6-OHDA injections were -anterior ⁄ posterior (AP), )1.8 mm; medial ⁄ lateral (ML), +2.0 mm; and dorsal ventral (DV), )8.6 mm relative to bregma with the incisor bar positioned 3.3 mm below the interaural line (Paxinos & Watson, 1998) . Using a 10 lL Hamilton syringe attached to a 26 gauge needle, 6-OHDA (12 lg) dissolved in 0.9% NaCl + 0.1% ascorbic acid was infused through a small burr hole in the skull at a rate of 2 lL ⁄ min for a total volume of 4 lL. The needle was withdrawn 5 min later. Following surgery, all rats were placed in clean cages on a warming pad for recovery, after which they were returned to group housing (two rats per cage). Soft chow was provided as needed to facilitate recovery during the first week after surgery. To minimize pain, rats were injected with buprenorphine (0.03 mg ⁄ kg) prior to surgery, 6 h after surgery, and the following morning. All rats were allowed to recover for 3 weeks before testing commenced.
Pharmacological treatments and design
L-DOPA priming At 3 weeks after lesion surgery, all rats were administered l-DOPA methyl ester (12 mg ⁄ kg, s.c.; Sigma) + DL-serine 2-(2,3,4-trihydroxybenzyl) hydrazide hydrochloride (benserazide; 15 mg ⁄ kg, s.c.; Sigma), hereafter denoted as l-DOPA, once daily for 7 days to induce stable and reliable LID (Putterman et al., 2007; Bishop et al., 2009) . l-DOPA and benserazide were dissolved in vehicle (0.9% NaCl containing 0.1% ascorbic acid) and administered at a volume of 1 mL ⁄ kg. All lesioned rats displaying a cumulative axial, limb and orolingual (ALO) AIMs score of > 30 on the seventh day of priming were used in the current study (29 of 38). Experiments outlined below continued on day 8 and testing occurred every third or fourth day until studies were completed.
Experiment 1
Effects of selective serotonin reuptake inhibitors on L-DOPA-induced abnormal involuntary movements and rotations
To determine whether SERT inhibition modified l-DOPA-induced ALO AIMs and rotations, one group of rats (n = 12) received the various counterbalanced doses of the SSRIs citalopram (vehicle, 1, 3 and 5 mg ⁄ kg, i.p.) and then paroxetine (vehicle, 0.3, 0.5 and 1.25 mg ⁄ kg, i.p.) in a within-subjects design. Another group of rats (n = 11) received various counterbalanced doses of fluoxetine (vehicle, 5, 10 and 20 mg ⁄ kg, i.p.) in a within-subjects design. During test days, at 30 min after SSRI treatments, l-DOPA (6 mg ⁄ kg + 15 mg ⁄ kg benserazide, s.c.) was administered and AIMs and rotations were scored every 10 min for 3 h.
Effects of selective serotonin reuptake inhibitors on L-DOPA efficacy
To determine whether the antiparkinsonian efficacy of l-DOPA was compromised by SERT inhibition, rats in the aforementioned groups were also tested for alterations in motor performance. To do so, one group received counterbalanced doses of citalopram (vehicle, 3 and 5 mg ⁄ kg, i.p.) and then, 1 week later, to allow a washout period, paroxetine (vehicle, 0.5 or 1.25 mg ⁄ kg, i.p.). The other group received counterbalanced doses of fluoxetine (vehicle, 10, 20 mg ⁄ kg, i.p.) at 30 min prior to 6 mg ⁄ kg l-DOPA, 60 min after which L-DOPA efficacy was examined using the forepaw adjusting steps (FAS) test (Chang et al., 1999; Bishop et al., 2009) .
Effects of dopamine lesions, L-DOPA and selective serotonin reuptake inhibitors on striatal and raphe monoamines In order to better understand the neurochemical mechanism(s) by which SSRIs may be modifying behavior, rats from Experiment 1 were divided into three equally dyskinetic groups (n = 7-8 ⁄ group) and were randomly assigned to treatment with either vehicle + vehicle, vehicle + l-DOPA (6 mg ⁄ kg, s.c.) or citalopram (5 mg ⁄ kg, i.p.) + l-DOPA (6 mg ⁄ kg, s.c.) with injections 1 and 2 spaced 30 min apart. At 60 min after the second injection, rats were decapitated, the left and right striata and the dorsal raphe were dissected, and tissue was immediately flash frozen for subsequent analysis of monoamine and metabolite content by HPLC.
Experiment 2
Dose-dependent effects of apomorphine on abnormal involuntary movements and rotations Apomorphine, a non-selective DA receptor agonist, has been shown to induce dyskinesia in animal models of PD and patients with PD by direct DA receptor stimulation (Di Chiara & Gessa, 1978; Verhagen Metman et al., 1997; Fox et al., 2001; Papathanou et al., 2011) . To establish a dose-response for apomorphine, l-DOPA-primed rats (n = 6) were injected with various doses of the compound (vehicle, 0.025, 0.05, 0.1 mg ⁄ kg, s.c.) in a counterbalanced within-subjects design. On test days, AIMs and rotations were scored every 10 min for 90 min.
Effects of selective serotonin reuptake inhibitors on apomorphine-induced abnormal involuntary movements and rotations
In order to examine whether the antidyskinetic effects of SSRIs were acting pre-synaptically or post-synaptically, doses of paroxetine (0.5 mg ⁄ kg, i.p.) citalopram (3 mg ⁄ kg, i.p.) and fluoxetine (10 mg ⁄ kg, i.p.) shown to reduce l-DOPA-induced AIMs in Experiment 1 were tested against apomorphine. Rats from the aforementioned doseresponse study received SSRIs at 30 min prior to apomorphine (0.05 mg ⁄ kg, s.c.) in a counterbalanced, within-subjects design. On test days, AIMs and rotations were scored every 10 min for 90 min.
Behavioral analyses
Abnormal involuntary movements and rotations
Rats were monitored for AIMs using a procedure described previously (Lindenbach et al., 2011) and similar to that initially depicted by Lundblad et al. (2002) with slight modifications. On test days (09:00-14:00 h), rats were individually placed in plexiglass cylinders (22.2 cm diameter, 25.4 cm high; Thermo Fisher Scientific, Rochester, NY, USA) at 5 min prior to pre-treatments. Following l-DOPA injection, a trained observer who was blind to treatment condition assessed each rat for the exhibition of ALO AIMs. Each new rater was trained for a minimum of three sessions and then correlated with a well-trained instructor. A correlation of ‡ 90% with the instructor was required before new raters could score AIMs. In addition, contralateral rotations, defined as complete 360°turns away from the lesioned side of the brain, were tallied. Dystonic posturing of the neck and torso, involving positioning of the neck and torso in a twisted manner directed toward the side of the body contralateral to the lesion, were referred to as 'axial' AIMs. 'Forelimb' AIMs were defined as rapid, purposeless movements of the forelimb located on the side of the body contralateral to the lesion. 'Orolingual' AIMs were composed of repetitive openings and closings of the jaw and tongue protrusions. The movements were considered abnormal as they occurred at times when the rats were not chewing or gnawing on food or other objects. For the l-DOPA dose-response experiment, ALO AIMs and rotations were recorded for 1 min, every 20th min for 2 h. For all other experiments, AIMs and rotations were recorded for 1 min, every 10th min for 3 h. During the AIMs observation period, a severity score of 0-4 was assigned for each AIMs category -0, not present; 1, present for less than 50% of the observation period (i.e. 1-29 s); 2, present for 50% or more of the observation period (i.e. 30-59 s); 3, present for the entire observation period (i.e. 60 s) and interrupted by a loud stimulus (a tap on the cylinder); or 4, present for the entire observation period but not interrupted by a loud stimulus. For each AIMs category, the scores were summed for the entire 2 or 3 h period.
Forepaw adjusting steps
The FAS test is a measure of forelimb akinesia and rats with > 80% unilateral DA depletion perform poorly with the lesioned forepaw (Chang et al., 1999) . l-DOPA reduces this deficit so that the test can be used to determine if an l-DOPA adjunct is interfering with the relief of PD symptoms provided by l-DOPA . To do so, an experimenter held the rat's hindlimbs and one forelimb such that the free forelimb was forced to bear the rat's body weight. Rats were then moved laterally for 90 cm over 10 s across a marked surface while another experimenter counted the number of steps taken in the forehand direction (defined as movement toward the rat's midline) and backhand direction (movement distal to the rat's midline). Each FAS test consisted of three backhand and three forehand trials with each limb, for a total of 12 trials per rat. The score for percent intact stepping was derived by taking the sum of the total steps with the lesioned forepaw, dividing that number by the total steps with the unlesioned forepaw and multiplying the outcome by 100. Lower percent intact scores indicate greater forelimb akinesia. Prior to FAS testing with the compounds of interest, all rats received three separate acclimation periods to reduce potential practice effects.
High-performance liquid chromatography
To determine the cerebral levels of monoamines, their metabolites, and monoamine turnover (a ratio of metabolite : monoamine), tissue samples were prepared for HPLC. Each sample was homogenized in a solution of ice-cold perchloric acid (0.1 m), 1% ethanol, and 0.02% EDTA. Subsequent homogenates were spun for 30 min at 14 400 g with the temperature maintained at 4°C. Aliquots of supernatant were then analyzed for the abundance of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), 5-HT, and 5-hydroxyindole-3-acetic acid using reverse-phase HPLC coupled to electrochemical detection according to the protocol of Kilpatrick et al. (1986) . The system employed consisted of an autoinjector (Model 542), a solvent delivery system (Model 582), a Guard-Pak column, a C-18 (100 · 4.6 mm, 5 lm packing) column, a Coulochem III electrochemical detector connected to an analytical cell (Model 5011A) located immediately after the column, a guard cell (Model 5020) positioned prior to the autoinjector, and an external pulse dampener (all from ESA). Samples were chromatographically separated using a mobile phase composed of 90 mm sodium dihydrogen phosphate (monobasic, anhydrous), 0.05 mm EDTA, 1.7 mm octane sulfonic acid and 10% (v : v) acetonitrile, adjusted to pH 3.0 with o-phosphoric acid. The first electrode of the analytical cell was set to a potential of )100 mV and the second electrode to +250 mV. The guard cell had a potential of 350 mV. As monoamines and metabolites eluted from the column and passed through the analytical cell, they were oxidized at the second electrode and a spike in current was generated. This signal was recorded as a trace of electrode current vs. time by ezchrom elite software via a Scientific Software, Inc. (SS420v) module. Each compound was detected as a peak in this trace, and the ezchrom elite software was used to calculate peak areas. Peak areas were converted to picograms of compound using a standard curve made from samples of known monoamine and metabolite concentrations (1e -6 -1e -9 M), normalized to striatal and raphel tissue weights, and expressed as pg of compound ⁄ mg of tissue (mean ± SEM).
Statistical analyses
All parametric data (HPLC, rotations and FAS) were expressed as mean ± SEM. Non-parametric ALO AIMs data were expressed as medians ± median absolute deviation. HPLC-derived striatal and raphe monoamine and metabolite levels and turnover ratios were analyzed by two-factor (Side · Treatment) and one-factor (Treatment) anovas, respectively. ALO AIMs were analyzed by non-parametric Friedman anovas at each time point or over the 3 h period. When appropriate, parametric Fisher LSD or non-parametric Wilcoxon posthoc tests were employed. All statistical analyses were performed with the use of statistica software version 10 (Statsoft Inc., Tulsa, OK, USA). Alpha was set at 0.05.
Results
Experiment 1
Selective serotonin reuptake inhibitors dose-dependently attenuate L-DOPA-induced axial, limb, and orolingual abnormal involuntary movements and rotations Three doses of each SSRI were tested in l-DOPA-primed rats to determine their effects on l-DOPA-induced AIMs and rotations. Statistical analyses of dose (bar graph insets) and dose at each time point (time courses), depicted in Fig. 1A-C , revealed that all SSRIs dose-and time-dependently reduced ALO AIMs (all v 2 , df 3 > 9.8, all P < 0.05). At each dose tested, paroxetine pre-treatment attenuated LID, with increasing doses enhancing and prolonging the antidyskinetic effects. Citalopram also reduced ALO AIMs in a dose-and time-dependent manner although the lowest dose was only mildly effective. The effects of fluoxetine pre-treatment were similar to paroxetine and citalopram, with the reduction in LID being most pronounced with the highest dose. Paroxetine, citalopram and fluoxetine (Fig. 1D-F ) also modified l-DOPA-induced rotations with analyses demonstrating dose · time interactions for each (F 51,459 = 3.20, P < 0.01; F 51,561 = 3.60, P < 0.01; F 51,510 = 4.06, P < 0.01, respectively). The pattern of these effects was, by and large, a reflection of those seen for ALO AIMs, although fluoxetine produced more pronounced effects on rotations.
L-DOPA efficacy is not altered by selective serotonin reuptake inhibitor administration
In order to determine whether the antiparkinsonian efficacy was altered by SSRI pre-treatment, rats were pre-treated with antidyski- netic doses of each compound followed by l-DOPA. Motor performance using the FAS was measured 60 min later. Analyses of the results shown in Fig. 2A -C demonstrated main effects of treatment for paroxetine (F 3,33 = 11.24, P < 0.001), citalopram (F 3,33 = 8.36, P < 0.001) and fluoxetine (F 3,30 = 14.84, P < 0.001). Further posthoc analyses revealed that l-DOPA significantly reversed lesioninduced stepping deficits (P < 0.05) and that both doses of paroxetine and citalopram, when combined with l-DOPA, maintained this antiparkinsonian effect (P < 0.05 vs. vehicle treatments). Interestingly, whereas the lower dose of fluoxetine did maintain l-DOPA's efficacy above vehicle treatment (P < 0.05), the higher dose reduced the antiparkinsonian effects.
Dopamine lesions, L-DOPA and selective serotonin reuptake inhibitors alter striatal and raphe monoamines
The HPLC analysis of striatal and raphe monoamines was used to examine the possible effects of lesion, l-DOPA and SSRI administration in unilateral 6-OHDA-lesioned, l-DOPA-primed rats (n = 7-8 ⁄ group). Subjects were killed at 60 min after receiving vehicle treatments, vehicle and l-DOPA or citalopram (5 mg ⁄ kg, i.p.) and l-DOPA (6 mg ⁄ kg, s.c.). The results are shown in Table 1 .
Within the striatum, analyses of DA revealed main effects of lesion side (F 1,20 = 763.77, P < 0.001) and treatment (F 2,20 = 3.93, P < 0.05), indicating that DA levels were reduced by lesion and that l-DOPA treatment increased DA regardless of citalopram. Striatal DOPAC was also reduced by lesion (F 1,20 = 310.63, P < 0.001), although no significant effects of treatment were observed. A main effect of side (F 1,20 = 35.79, P < 0.001) demonstrated that DA turnover was increased preferentially in the DA-lesioned hemisphere (P < 0.05). Striatal 5-HT tissue content was altered significantly by lesion (F 1,20 = 4.35, P < 0.05) and treatment (F 2,20 = 3.79, P < 0.05). Post-hoc analyses showed that lesion reduced the overall 5-HT levels, whereas citalopram increased 5-HT regardless of hemisphere, in corroboration of its putative pharmacological actions. Striatal 5-hydroxyindole-3-acetic acid was also altered by lesion and treatment (F 1,20 = 33.94, P < 0.01; F 2,20 = 4.77, P < 0.05, respectively). Post-hoc analysis of these main effects demonstrated that lesion increased, whereas citalopram reduced 5-hydroxyindole-3-acetic acid. Analysis of striatal 5-HT turnover demonstrated both side (F 1,20 = 18.73, P < 0.001) and treatment (F 2,20 = 5.49, P < 0.05) main effects. Further post-hoc analyses indicated that lesion increased turnover and citalopram treatment suppressed turnover (all P < 0.05).
In order to better understand the neurochemical alterations at 5-HT cell bodies, monoamine tissue content was also examined in the dorsal raphe of these same rats. Main effects of treatment were found for DA (F 2,20 = 6.83, P < 0.01), DOPAC (F 2,20 = 11.94, P < 0.001) and DA turnover (F 2,20 = 4.12, P < 0.05). 5-HT (F 2,20 = 4.84, P < 0.05) and 5-HT turnover (F 2,20 = 11.79, P < 0.001) main effects were also observed. Raphe DA levels were found to be significantly increased by combined citalopram + l-DOPA treatment, DOPAC levels were increased in the raphe regardless of citalopram (all, P < 0.05) and l-DOPA treatment increased DA turnover. Similar to the striatum, citalopram, when combined with l-DOPA, augmented 5-HT levels in raphe tissue (P < 0.05). 5-HT turnover was increased by l-DOPA and significantly reduced by citalopram co-administration (P < 0.05), again supporting the actions of this SSRI on 5-HT neurotransmission.
Experiment 2
Apomorphine dose-dependently induces abnormal involuntary movements
As a way to determine whether the antidyskinetic effects of SSRIs occur via post-synaptic influences, a dose-response for AIMs and rotations induced by the non-selective DA agonist apomorphine was . FAS were evaluated at 60 min after the final treatments. Values (as means + SEM) are expressed as percent stepping with the lesioned forepaw vs. intact forepaw. Significant differences were determined by one-way anovas for each SSRI. When appropriate, treatment differences were analyzed with Fischer least squares design (LSD) post-hoc analyses. *P < 0.05 vs. vehicle + vehicle; + P < 0.05 vs. vehicle + l-DOPA;^P < 0.05 vs. fluoxetine (10 mg ⁄ kg, i.p.) + l-DOPA. first established. As shown in Fig. 3A and B, apomorphine dose-and time-dependently induced ALO AIMs and rotations as indicated by main effects of treatment for ALO AIMs (v 2 , df 3 = 14.60; P < 0.01) and rotations (treatment effect -F 3,15 = 26.33, P < 0.001), as well as treatment · time effects from 10-50 min post-injection (AIMs -v 2 , df 3 > 12.0; all P < 0.05; rotations -F 24,120 = 3.94, all post-hoc analyses, P < 0.001). Based on this dose-response, a test dose of 0.05 mg ⁄ kg (s.c.) apomorphine was chosen for the final experiment.
Selective serotonin reuptake inhibitors do not alter apomorphine-induced abnormal involuntary movements Doses of paroxetine (0.5 mg ⁄ kg), citalopram (3 mg ⁄ kg) and fluoxetine (10 mg ⁄ kg), shown to reduce l-DOPA-induced AIMs, were administered at 30 min prior to apomorphine (0.05 mg ⁄ kg), after which ALO AIMs and rotations were examined. As shown in Fig. 3C , SSRI pre-treatment did not alter apomorphine-induced dyskinesia (AID) at doses shown to convey antidyskinetic effects against l-DOPA. Surprisingly, examination of the effect of SSRI treatment on apomorphine-induced rotations (Fig. 3D ) revealed a main effect of treatment (F 3,15 = 7.72, P < 0.01), which post-hoc analyses indicated was a result of enhanced rotations in fluoxetine-treated subjects compared with all other conditions (all P < 0.05).
Discussion
In the present study, several findings support further exploration of SERT inhibition as a potential adjunctive approach to l-DOPA pharmacotherapy in PD and shed light upon possible mechanism(s) of action. First, acute administration of the SSRIs citalopram, paroxetine and fluoxetine conveyed dose-dependent antidyskinetic effects in l-DOPA-primed rats. Second, at antidyskinetic doses, the antiparkinsonian efficacy of l-DOPA was not modified. Finally, SERT blockade did not alter dyskinesia induced by the direct DA agonist apomorphine, suggesting that the putative therapeutic effects of SSRIs likely occur by alterations in pre-synaptic processes.
Accumulating evidence over the past few years has implicated a more primary role for the 5-HT system in the development and expression of LID. 5-HT neurons can transport exogenously administered l-DOPA into the cytosol, convert it to DA via amino acid decarboxylase, package l-DOPA-derived DA into vesicles via vesicular monoamine transporters and release it as a 'false neurotransmitter' (Ng et al., 1970; Arai et al., 1995; Kannari et al., 2000; Carta et al., 2007) . Although the contribution of 5-HT neurons to the pool of l-DOPA-derived DA is likely limited to advanced stages of PD when the majority of DA neurons have degenerated, this is also when patients are most likely to experience LID (Troiano et al., 2009; Nutt & Nygaard, 2011) . Thus, in latestage PD, 5-HT neurons, which lack the autoregulatory DA transporters and DA D2 receptors, may be releasing l-DOPAderived DA in a pulsatile and unregulated manner that leads to LID (Nutt et al., 2000; de la Fuente-Fernández et al., 2004) . Therefore, antidyskinetic strategies have focused on ways to temper extraphysiological DA release from 5-HT neurons by targeting the inhibitory 5-HT 1 agonists. Such a strategy has proven somewhat beneficial (Bonifati et al., 1994; Bara-Jimenez et al., 2005; Goetz et al., 2007) , although translation of these compounds to the clinic remains an unmet goal.
Another less studied target with potential to modulate l-DOPAderived DA neurotransmission is SERT. Striatal SERT is both upregulated in dyskinetic rats, monkeys and humans and has been shown to be accompanied by an increased density of striatal 5-HT innervation (Rylander et al., 2010) . Although such neuroplasticity Table 1 . between sides (striata contralateral vs. ipsilateral to lesion), treatments and side · treatment interactions were determined by one-way and two-way anovas.
Individual cell differences were analyzed with Fischer least squares design (LSD). *P < 0.05 vs. vehicle + vehicle; P < 0.05 vs. vehicle + l-DOPA.
does not establish a causal link between SERT-expressing terminals and LID, removal of 5-HT terminals from raphestriatal projections has been demonstrated to reduce LID (Carta et al., 2007; Eskow et al., 2009) . Therefore, in order to better examine the potential role of SERT in LID and its treatment, the current study set out to systematically address the effects of SERT blockade on the expression of AIMs in a rodent model of dyskinesia.
In the first experiment we found that each SSRI dose-and timedependently reduced the expression of ALO AIMs. The highest doses of each SSRI produced a > 75% reduction in AIMs; however, the magnitude and timing of these effects were dependent on the compound, likely reflecting differential pharmacological properties for SERT affinity (paroxetine > citalopram > fluoxetine) and SERT selectivity over DA and norepinephrine transporters (citalopram > fluoxetine > paroxetine) (Owens et al., 1997; Tatsumi et al., 1997; Bymaster et al., 2002) . Interestingly, rotations were also markedly reduced by SSRIs. Although the utility of measuring rotational activity remains debatable , these findings may have reflected both antidyskinetic effects and alterations in l-DOPA efficacy, as discussed below. Although the present work is the first systematic study of SERT inhibition on LID, several other studies have demonstrated similar effects. For example, Dekundy et al. (2007) reported that a lower dose of fluoxetine (5 mg ⁄ kg) produced a mild, although non-significant reduction in AIMs in l-DOPA-primed rats. Kuan et al. (2008) found that chronic administration of citalopram, at a high dose (40 mg ⁄ kg), attenuated l-DOPA-induced AIMs and rotational activity in 6-OHDA-lesioned rats. Potential antidyskinetic effects of SERT blockade for LID treatment have also been reported in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates (Huot et al., 2011; Johnston et al., 2012) . It remains to be determined whether the pronounced antidyskinetic effects of SSRIs in our rat model will translate to the patient with PD. The few studies that have addressed this question varied in method. Durif et al. (1995) reported that fluoxetine reduced AID in l-DOPAresponsive patients with PD, whereas Chung et al. (2005) , using intravenous l-DOPA, reported no significant change in LID in patients co-administered paroxetine. Further work is required to discern a potential antidyskinetic benefit in the clinical population.
One controversial concern regarding the use of SSRI treatment in PD is the potential for the deterioration of l-DOPA efficacy (Leo, 1996; Rampello et al., 2002) . In the present study, this possibility was highlighted by the dose-dependent reduction in rotations observed with each SSRI. Therefore, in order to determine whether SSRI treatment also altered l-DOPA's antiparkinsonian properties, rats were subject to the FAS test (Schallert et al., 1979; Olsson et al., 1995; Chang et al., 1999; Eskow et al., 2007) . In the present study, the pronounced motor performance deficits produced by DA lesions were significantly reversed by l-DOPA treatment. More importantly, antidyskinetic doses of the SSRIs maintained l-DOPA's antiparkinsonian efficacy. The one exception to this effect was the highest dose of fluoxetine (20 mg ⁄ kg), which appeared to attenuate l-DOPA's beneficial effects on motor performance. This is interesting given clinical reports that fluoxetine can exacerbate PD symptoms in a small subset of patients (Caley & Friedman, 1992; Steur, 1993 et al., 1995). That said, most studies report either no deleterious motor consequence or improvement in motor symptoms with SSRI treatment in patients with PD (Ceravolo et al., 2000; Rampello et al., 2002; Chung et al., 2005) . Moreover, although qualitative in assessment, we did not observe a drug-induced suppression of motor activity in SSRItreated rats. In fact, in the first 30 min of testing, these rats often reared, touching the sides of the cylinder with both forepaws. However, across testing days, rats tended to acclimate to the environment, confounding quantitative assessments. These observations corroborate previous work showing that similar SSRI doses did not alter locomotor activity in intact rats (Lightowler et al., 1994; Griebel et al., 1997; Szewczyk et al., 2009) . Although the aforementioned behavioral findings strongly support the targeting of SERT inhibition as an antidyskinetic strategy, the mechanisms by which these compounds convey their effects remain largely unexplored. In order to better understand this, we examined the effects of DA lesion, l-DOPA treatment and citalopram treatment (5 mg ⁄ kg) on monoamine function in the striatum and dorsal raphe. As expected, 6-OHDA injections produced severe loss of striatal DA and its metabolite DOPAC, whereas DA turnover was augmented by lesion, likely reflecting a compensatory response to DA loss (Zigmond et al., 1984; Dupre et al., 2007) . It is notable that DA lesions also reduced 5-HT, but increased 5-hydroxyindole-3-acetic acid and 5-HT turnover. Interestingly, citalopram corrected these imbalances in the lesioned striatum, increasing 5-HT and reducing 5-HT turnover, commensurate with SSRI's putative pharmacological and antidepressant actions in the parkinsonian brain (Perry & Fuller, 1992; Honig et al., 2009) . Lesion and intact side comparisons within the midline dorsal raphe were not possible, as cell bodies and ascending 5-HT fibers were intermixed (Björklund et al., 1971) ; however, treatments affected several neurochemical indices. One of the more intriguing effects occurred following combined l-DOPA and citalopram treatment, where SERT inhibition led to increased local DA levels. l-DOPA and citalopram also significantly increased raphe 5-HT levels and reduced 5-HT turnover, suggesting that increased 5-HT tone proximal to dorsal raphe neurons may lead to the stimulation of local 5-HT 1A autoreceptors responsible for the effects of SSRIs on LID (Kreiss & Lucki, 1994; Yamato et al., 2001; Eskow et al., 2007) . This is also in concert with previous work demonstrating that the antidyskinetic effects of the SERT-acting compounds 3,4-methylenedioxymethamphetamine and fenfluramine are conveyed in part via indirect stimulation of 5-HT 1A receptors (Bishop et al., 2006; Iravani et al., 2003) .
As an additional way to examine the mechanism(s) by which SERT inhibition reduces LID, we tested whether SSRIs modified dyskinesia evoked by direct DA receptor stimulation by apomorphine. This question originated from a rich literature describing the integral role of post-synaptic signaling in the development and expression of LID (for examples see Feyder et al., 2011; Gerfen & Surmeier, 2011) . Under these circumstances, SSRIs did not alter AID. In fact, fluoxetine actually augmented apomorphine-induced rotations. This discrepancy between the antidyskinetic effects of SERT blockade for LID vs. AID along with the neurochemical results implicate the pre-synaptic modulation of monoaminergic function as a mechanism for SSRI's effects as direct DA receptor stimulation bypasses l-DOPA uptake, conversion and release.
Despite the clear pre-clinical benefits, it remains to be determined whether the pronounced antidyskinetic effects of SSRIs in our rat model will translate to patients. SSRIs are ubiquitously employed for the treatment of depression and anxiety in PD (Richard & Kurlan, 1997; Weintraub et al., 2003) . However, despite their utility for the treatment of mood dysfunction, the few studies that have addressed SSRI effects on LID have varied in question and method. Durif et al. (1995) reported that fluoxetine reduced AID in l-DOPA-responsive patients with PD, whereas Chung et al. (2005) , using intravenous l-DOPA, reported no significant change to LID in patients co-administered paroxetine. Further work is clearly required to discern the potential antidyskinetic benefits of SERT inhibition in the clinical population.
In conclusion, this present pre-clinical work demonstrated that common, FDA-approved SSRIs were able to attenuate the expression of LID in hemi-parkinsonian rats. Several important questions remain regarding the translation of these findings to the clinic, the mechanism by which these compounds work, and the long-term efficacy of the purported antidyskinetic effects. Finally, the current study complements the accumulating literature supporting the 5-HT system as a target for the improved treatment of patients with PD.
